Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

May 12, 2020 | Press Releases

MARLBOROUGH, Mass., May 12, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020

May 4, 2020 | Press Releases

MARLBOROUGH, Mass., May 4, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market

Apr 2, 2020 | Press Releases

MARLBOROUGH, Mass., April 2, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market

Mar 31, 2020 | Press Releases

MARLBOROUGH, Mass., March 31, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform’s Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth

Mar 31, 2020 | Press Releases

Animal studies show a complete and statistically significant (p <0.0001) inhibition of tumor growthMARLBOROUGH, Mass., March 31, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology...